Radiotherapy after breast-conserving surgery for women aged 70 and older yields a five-year overall survival rate of 88.8%, compared with 82.3% for patients who do not receive the treatment, according to a study published on Tuesday.
The research, published in the International Journal of Women’s Health, examined 8,934 patients diagnosed between 2016 and 2017 with hormone receptor-positive, T1-2N0M0 breast cancer, drawing on population-based data from the Surveillance, Epidemiology, and End Results (SEER) program. Linyue Sun, Xinian Jiang, Ziyu Chen, Peilin Chen, Yuanzhi Li, and Fenghua Zhang conducted the Propensity Score-Matched SEER Study to evaluate whether postoperative radiation can be safely omitted in older patient cohorts.
Among 2,591 propensity-matched pairs evaluated in the research, the cumulative incidence of breast cancer death reached 1.33% with radiotherapy and 2.80% without it. The authors utilized propensity score matching and inverse probability of treatment weighting to control for measured confounding, finding that radiation was associated with lower all-cause mortality and a reduced cause-specific hazard of breast cancer death.
Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, stated on LinkedIn that the findings give reason to be cautious about using age alone to recommend omitting radiotherapy. Mokbel pointed out that SEER lacked specific information on patient frailty, underlying comorbidities, and adherence to endocrine therapy.
“How much of that survival difference can we attribute to radiotherapy?” Mokbel asked in remarks published by Oncodaily, noting that of 718 total deaths recorded in the matched cohort, 598 were confirmed to stem from other causes. Healthier patients may have received radiotherapy more frequently, and propensity matching cannot fully adjust for unmeasured health disparities.
Contrasting population registry data with randomized clinical trial evidence, Mokbel highlighted the PRIME II trial as a provider of firmer estimates regarding what radiotherapy achieves in carefully selected older patients receiving endocrine therapy. At 10 years, local recurrence rates reached 9.5% without radiotherapy versus 0.9% with it, while overall survival hovered at approximately 81% in both trial arms, according to Oncodaily – Oncology News, Insights, Stories.
“In my practice, I would offer omission as an option to a woman who meets the trial criteria,” Mokbel told Oncodaily – Oncology News, Insights, Stories. “I would also explain what radiotherapy achieved for women like her: about nine fewer local recurrences per 100 women over 10 years.”
Shared decision-making must incorporate individual tumor characteristics, patient life expectancy, the likelihood of maintaining endocrine therapy, and how much value a patient places on avoiding a subsequent breast operation, Mokbel noted.
Keep reading